Research & Development

Can ZMA001 Revolutionize PAH Treatment With FDA Orphan Drug Designation?
Research & Development Can ZMA001 Revolutionize PAH Treatment With FDA Orphan Drug Designation?

Pulmonary arterial hypertension (PAH) is a debilitating and life-threatening condition characterized by the blockage and narrowing of pulmonary arterioles. Current treatment options primarily focus on symptomatic relief, especially through the use of vasodilators. These medications help widen blood

FDA Approves Leqselvi for Severe Alopecia Areata, A JAK Inhibitor
Research & Development FDA Approves Leqselvi for Severe Alopecia Areata, A JAK Inhibitor

The FDA's recent approval of a new treatment for severe alopecia areata marks a significant advance in addressing this challenging condition. Deuruxolitinib, branded as Leqselvi and developed by Sun Pharmaceutical Industries, will now compete with existing treatments from Eli Lilly and Pfizer,

Cartesian’s Descartes-08 Shows Promise in Myasthenia Gravis; Market Wary
Research & Development Cartesian’s Descartes-08 Shows Promise in Myasthenia Gravis; Market Wary

The field of autoimmune disease treatment is witnessing groundbreaking innovations, with Cartesian Therapeutics making headlines for its latest Phase 2 clinical trial results of Descartes-08. This experimental cell therapy aims to bring hope to patients suffering from myasthenia gravis, a rare and

Artiva’s $167M IPO Signals Shift to Allogeneic Therapies for Autoimmune Diseases
Research & Development Artiva’s $167M IPO Signals Shift to Allogeneic Therapies for Autoimmune Diseases

Artiva Biotherapeutics has made headlines with its successful initial public offering (IPO), raising an impressive $167 million. This significant milestone not only highlights Artiva's strategic pivot toward autoimmune disease treatments using donor-derived cell therapies but also marks a

SK Biopharma Secures $571.5M Deal with Full-Life for Cancer Drug FL-091
Research & Development SK Biopharma Secures $571.5M Deal with Full-Life for Cancer Drug FL-091

The recent $571.5 million licensing agreement between SK Biopharmaceuticals Co., Ltd., and Full-Life Technologies Limited marks a significant milestone in the biotech industry. This exclusive deal grants SK Biopharmaceuticals the rights to develop, manufacture, and commercialize FL-091, an

Can Roche's New Obesity Pill CT-996 Revolutionize Weight Loss?
Research & Development Can Roche's New Obesity Pill CT-996 Revolutionize Weight Loss?

The global obesity epidemic has led to an urgent demand for innovative and effective treatments. Traditional methods like diet, exercise, and surgical interventions present various challenges, often marked by inconsistent results and reduced patient compliance. In response, the pharmaceutical

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later